| Nov 18 |
Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know
|
| Nov 15 |
Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Nov 13 |
Sutro Biopharma GAAP EPS of -$0.59 beats by $0.14, revenue of $8.5M misses by $6.76M
|
| Nov 13 |
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates
|
| Nov 13 |
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
|
| Nov 7 |
Why Lyft Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket
|
| Nov 4 |
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
|
| Nov 4 |
Sutro Biopharma begins trial of acute myeloid leukaemia treatment in children
|
| Nov 1 |
Sutro Biopharma Announces Initiation of the Registration-enabling REFRĪ±ME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
|
| Oct 20 |
Sutro Biopharma (NASDAQ:STRO) shareholders have endured a 80% loss from investing in the stock three years ago
|
